GL1X · GenesisL1 explorer

Research workbench

Structure of ctx-M-15 E166Q mutant crystallised in the presence of tazobactam (AAI101)

Analyse Structure of ctx-M-15 E166Q mutant crystallised in the presence of tazobactam… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7BDR
Type
protein
Length
259 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Beta-lactamase
EC
3.5.2.6
UniProt
W1EPV7
Ligands
NA, SO4, CL
Pockets
1 · best druggability 0.39

Structure

x-ray diffraction · 1 distinct chain · 43% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase (EC 3.5.2.6)protein25943% helix, 19% strandW1EPV7

Ligands and binding sites

  • NA · Sodium ion · metal · chains A
  • SO4 · Sulfate ion · ion · 2 copies · chains A
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11230.390.7526empty

Modifications

Observed in the structure: 1 d-amino (D-amino acid).

Compared structures

  • 7BDR · Structure of CTX-M-15 E166Q mutant crystallised in the presence of tazobactam (AAI101) · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.